| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
|
Duong, Jennifer T
|
|
|
23 |
3 |
p. 490-498
|
artikel
|
| 2 |
A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy
|
Taylor-Cousar, Jennifer L.
|
|
|
23 |
3 |
p. 412-416
|
artikel
|
| 3 |
A qualitative exploration of parenthood experiences and needs among people with cystic fibrosis
|
OM, Stransky
|
|
|
23 |
3 |
p. 424-428
|
artikel
|
| 4 |
Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids
|
Bass, Rosara
|
|
|
23 |
3 |
p. 481-489
|
artikel
|
| 5 |
Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis
|
Kazmerski, Traci M.
|
|
|
23 |
3 |
p. 417-423
|
artikel
|
| 6 |
Data accuracy, consistency and completeness of the national Swiss cystic fibrosis patient registry: Lessons from an ECFSPR data quality project
|
Wolf, Lara
|
|
|
23 |
3 |
p. 506-511
|
artikel
|
| 7 |
Developing a nutrition screening tool for children with cystic fibrosis ages 0 to 2 years
|
Bellini, Sarah Gunnell
|
|
|
23 |
3 |
p. 532-537
|
artikel
|
| 8 |
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
|
Shi, Alan
|
|
|
23 |
3 |
p. 566-572
|
artikel
|
| 9 |
ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals
|
De Wachter, E
|
|
|
23 |
3 |
p. 388-397
|
artikel
|
| 10 |
Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study
|
Kim, Claire
|
|
|
23 |
3 |
p. 436-442
|
artikel
|
| 11 |
Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study
|
van der Meer, Renske
|
|
|
23 |
3 |
p. 549-553
|
artikel
|
| 12 |
Factors associated with pubertal growth outcomes in cystic fibrosis
|
Patil, Rashmi
|
|
|
23 |
3 |
p. 538-544
|
artikel
|
| 13 |
Feasibility Testing of a Web-Based Reproductive Decision Support Tool for Cystic Fibrosis
|
Kazmerski, Traci M.
|
|
|
23 |
3 |
p. 404-411
|
artikel
|
| 14 |
Food insecurity screening and local food access: Contributions to nutritional outcomes among children and adults with cystic fibrosis in the United States
|
Bailey, Julianna
|
|
|
23 |
3 |
p. 524-531
|
artikel
|
| 15 |
Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant
|
Coman, Diana
|
|
|
23 |
3 |
p. 561-562
|
artikel
|
| 16 |
Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe
|
Sloan, Callum M.
|
|
|
23 |
3 |
p. 499-505
|
artikel
|
| 17 |
Key inflammatory markers in bronchoalveolar lavage predict bronchiectasis progression in young children with CF
|
Horati, Hamed
|
|
|
23 |
3 |
p. 450-456
|
artikel
|
| 18 |
Lymphocyte transformation tests predict delayed-type allergy to piperacillin/tazobactam in patients with cystic fibrosis
|
Roehmel, Jobst F.
|
|
|
23 |
3 |
p. 573-578
|
artikel
|
| 19 |
News article
|
Hughes, Dominic
|
|
|
23 |
3 |
p. 371-372
|
artikel
|
| 20 |
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
|
Young, Dave
|
|
|
23 |
3 |
p. 545-548
|
artikel
|
| 21 |
Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration
|
Hong, Eunjin
|
|
|
23 |
3 |
p. 519-523
|
artikel
|
| 22 |
Prevalence and impact of human papillomavirus (HPV) in adults with cystic fibrosis: A self-reported cross-sectional Canadian survey
|
Thornton, Christina S.
|
|
|
23 |
3 |
p. 398-403
|
artikel
|
| 23 |
Prevalence and severity of functional urinary and anorectal disorders and their impact on quality of life in cystic fibrosis
|
Hubeaux, Katelyne
|
|
|
23 |
3 |
p. 579-586
|
artikel
|
| 24 |
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
|
Mainz, Jochen G.
|
|
|
23 |
3 |
p. 474-480
|
artikel
|
| 25 |
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review
|
Testa, Ilaria
|
|
|
23 |
3 |
p. 554-560
|
artikel
|
| 26 |
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis
|
McNally, Paul
|
|
|
23 |
3 |
p. 429-435
|
artikel
|
| 27 |
Sexual & reproductive health in CF – A shared responsibility
|
Collins, Bethany
|
|
|
23 |
3 |
p. 373-374
|
artikel
|
| 28 |
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
|
Gramegna, Andrea
|
|
|
23 |
3 |
p. 375-387
|
artikel
|
| 29 |
Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor
|
Smeets, T.J.L.
|
|
|
23 |
3 |
p. 563-565
|
artikel
|
| 30 |
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
|
Donaldson, Scott H.
|
|
|
23 |
3 |
p. 457-460
|
artikel
|
| 31 |
The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis,
|
Rosenfeld, Margaret
|
|
|
23 |
3 |
p. 443-449
|
artikel
|
| 32 |
The roles and experiences of adolescents with cystic fibrosis and their parents during transition: A qualitative interview study
|
Wyngaert, Karsten Vanden
|
|
|
23 |
3 |
p. 512-518
|
artikel
|
| 33 |
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol
|
Bertolini, Anna
|
|
|
23 |
3 |
p. 461-473
|
artikel
|
Tijdschrift beschrijving